TY - JOUR
T1 - B-cell lymphomas, version 5.2021. Featured updates to the NCCN guidelines
AU - Zelenetz, Andrew D.
AU - Gordon, Leo I.
AU - Chang, Julie E.
AU - Christian, Beth
AU - Abramson, Jeremy S.
AU - Advani, Ranjana H.
AU - Bartlett, Nancy L.
AU - Budde, L. Elizabeth
AU - Caimi, Paolo F.
AU - de Vos, Sven
AU - Dholaria, Bhagirathbhai
AU - Fakhri, Bita
AU - Fayad, Luis E.
AU - Glenn, Martha J.
AU - Habermann, Thomas M.
AU - Hernandez-Ilizaliturri, Francisco
AU - Hsi, Eric
AU - Hu, Boyu
AU - Kaminski, Mark S.
AU - Kelsey, Christopher R.
AU - Khan, Nadia
AU - Krivacic, Susan
AU - LaCasce, Ann S.
AU - Lim, Megan
AU - Narkhede, Mayur
AU - Rabinovitch, Rachel
AU - Ramakrishnan, Praveen
AU - Reid, Erin
AU - Roberts, Kenneth B.
AU - Saeed, Hayder
AU - Smith, Stephen D.
AU - Svoboda, Jakub
AU - Swinnen, Lode J.
AU - Tuscano, Joseph
AU - Vose, Julie M.
AU - Dwyer, Mary A.
AU - Sundar, Hema
N1 - Publisher Copyright:
© 2021 Harborside Press. All rights reserved.
PY - 2021/11
Y1 - 2021/11
N2 - In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody–drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1–mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.
AB - In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody–drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1–mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.
UR - http://www.scopus.com/inward/record.url?scp=85120056761&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2021.0054
DO - 10.6004/jnccn.2021.0054
M3 - Article
C2 - 34781267
AN - SCOPUS:85120056761
SN - 1540-1405
VL - 19
SP - 1218
EP - 1230
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 11
ER -